Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Su NK"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Piccinelli S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Lampe L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Medical Department, Christian-Albrechts University, Kiel, Germany., Dong H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Vergara Cadavid J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Boiarsky R; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA., Papazian N; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Cao A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA., Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Ferrari de Andrade L; Precision Immunology Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai Hospital, New York, NY., Rahmat M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Shen Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Science Institute of Singapore, National University of Singapore Cancer Science, Singapore, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Blanco Fernández L; Clínica Universidad de Navarra, Center for Applied Medical Research, CIBERONC, IDISNA, Pamplona, Spain., Zabaleta A; Clínica Universidad de Navarra, Center for Applied Medical Research, CIBERONC, IDISNA, Pamplona, Spain., Günther A; Medical Department, Christian-Albrechts University, Kiel, Germany., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Krantz Family Center for Cancer Research and Deptartment of Pathology, Massachusetts General Hospital, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA., Sonneveld P; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Cupedo T; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Romee R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5365-5370.
Autor:
Detappe A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Nguyen HV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Window Therapeutics, Boston, MA, USA., Jiang Y; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Window Therapeutics, Boston, MA, USA., Agius MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Wang W; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA., Mathieu C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Kristufek SL; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA., Lundberg DJ; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Bhagchandani S; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Irene_Ghobrial@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Irene_Ghobrial@dfci.harvard.edu., Ghoroghchian PP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ppg@mit.edu.; Harvard Medical School, Boston, MA, USA. ppg@mit.edu., Johnson JA; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. jaj2109@mit.edu.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. jaj2109@mit.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. jaj2109@mit.edu.
Publikováno v:
Nature nanotechnology [Nat Nanotechnol] 2023 Sep; Vol. 18 (9), pp. 1116.
Autor:
Sklavenitis-Pistofidis R; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece., Lightbody ED; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Reidy M; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Tsuji J; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Aranha MP; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Heilpern-Mallory D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Huynh D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chong SJF; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hackett L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Haradhvala NJ; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Wu T; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Berrios B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Alberge JB; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dutta A; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Davids MS; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Papaioannou M; Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.; Hematology Unit, 1st Internal Medicine Department, AHEPA University Hospital, Thessaloniki, Greece., Getz G; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Ghobrial IM; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Manier S; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000, France.; Department of Hematology, CHU Lille, Lille University, 59000, France.
Publikováno v:
BioRxiv : the preprint server for biology [bioRxiv] 2023 Aug 03. Date of Electronic Publication: 2023 Aug 03.
Autor:
Dutta AK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Alberge JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Lightbody ED; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Boehner CJ; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Dunford A; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Sklavenitis-Pistofidis R; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Mouhieddine TH; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Cowan AN; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Su NK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Horowitz EM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Barr H; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Hevenor L; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Beckwith JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Perry J; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Cao A; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Lin Z; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Kuhr FK; Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania., Mastro RGD; Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania., Nadeem O; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Greipp PT; Department of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota., Stewart C; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Auclair D; Multiple Myeloma Research Foundation, Norwalk, Connecticut., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Cancer Center and Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Ghobrial IM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Publikováno v:
Cancer discovery [Cancer Discov] 2023 Feb 06; Vol. 13 (2), pp. 348-363.
Autor:
Detappe A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Nguyen HV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Window Therapeutics, Boston, MA, USA., Jiang Y; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Window Therapeutics, Boston, MA, USA., Agius MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Wang W; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA., Mathieu C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Kristufek SL; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA., Lundberg DJ; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Bhagchandani S; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Irene_Ghobrial@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Irene_Ghobrial@dfci.harvard.edu., Ghoroghchian PP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ppg@mit.edu.; Harvard Medical School, Boston, MA, USA. ppg@mit.edu., Johnson JA; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. jaj2109@mit.edu.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. jaj2109@mit.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. jaj2109@mit.edu.
Publikováno v:
Nature nanotechnology [Nat Nanotechnol] 2023 Feb; Vol. 18 (2), pp. 184-192. Date of Electronic Publication: 2023 Jan 26.
Autor:
Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Aranha MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Redd RA; Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA., Baginska J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Haradhvala NJ; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Graduate Program in Biophysics, Harvard University, Cambridge, MA 02138, USA., Hallisey M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dutta AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Savell A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Varmeh S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Heilpern-Mallory D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Ujwary S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Zavidij O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Aguet F; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Bustoros M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Mouhieddine TH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Wu T; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Flechon L; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000 Lille, France., Anand S; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Rosenblatt JM; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA., Zonder J; Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA., Vredenburgh JJ; St. Francis Hospital and Cancer Center, Hartford, CT 06105, USA., Boruchov A; St. Francis Hospital and Cancer Center, Hartford, CT 06105, USA., Bhutani M; Levine Cancer Institute, Charlotte, NC 28204, USA., Usmani SZ; Levine Cancer Institute, Charlotte, NC 28204, USA., Matous J; Colorado Blood Cancer Institute, Denver, CO 80218, USA., Yee AJ; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Jakubowiak A; University of Chicago Cancer Center, Chicago, IL 60637, USA., Laubach J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Manier S; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000 Lille, France; Department of Hematology, CHU Lille, Lille University, 59000 Lille, France., Nadeem O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Richardson P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Badros AZ; University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA., Mateos MV; University Hospital of Salamanca - Instituto de Investigación Biomédica de Salamanca, 37007 Salamanca, Spain., Trippa L; Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA., Getz G; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: gadgetz@broadinstitute.org., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: irene_ghobrial@dfci.harvard.edu.
Publikováno v:
Cancer cell [Cancer Cell] 2022 Nov 14; Vol. 40 (11), pp. 1358-1373.e8.
Autor:
Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Mouhieddine TH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Redd R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA., Lampe L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Faculty of Medicine, Kiel University, Kiel, Germany., Nilsson KI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., El-Khoury H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Nassar AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Adib E; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Bindra G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Abou Alaiwi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Trippa L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard T. H. Chan School of Public Health, Boston, MA., Steensma DP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Castillo JJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA; and., Treon SP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA; and., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2022 Apr 12; Vol. 6 (7), pp. 2230-2235.
Autor:
Shen YJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA., Mishima Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Shi J; State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.; Shanghai Institute of Biochemistry and Cell Biology (SIBCB), University of Chinese Academy of Sciences, Beijing, China., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA., Redd RA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA., Moschetta M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Manier S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Roccaro AM; ASST Spedali Civili di Brescia, Clinical Research Development and Phase I Unit, CREA Laboratory, Brescia, Italy., Sacco A; ASST Spedali Civili di Brescia, Clinical Research Development and Phase I Unit, CREA Laboratory, Brescia, Italy., Tai YT; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Mercier F; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA., Kawano Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Berrios B; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Doench JG; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA., Root DE; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA., Michor F; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA; and., Scadden DT; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.
Publikováno v:
Blood [Blood] 2021 Apr 29; Vol. 137 (17), pp. 2360-2372.
Autor:
Zavidij O; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Haradhvala NJ; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital, Boston, MA, USA.; Harvard Biophysics Graduate Program, Harvard University, Boston, MA, USA., Mouhieddine TH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sklavenitis-Pistofidis R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Cai S; Harvard Medical School, Boston, MA, USA.; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Boston, MA, USA., Reidy M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Rahmat M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Flaifel A; Harvard Medical School, Boston, MA, USA.; Specialized Histopathology Core, Brigham and Women's Hospital, Boston, MA, USA., Ferland B; Specialized Histopathology Core, Brigham and Women's Hospital, Boston, MA, USA., Su NK; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Agius MP; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Park J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Manier S; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Bustoros M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Huynh D; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Capelletti M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Berrios B; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Liu CJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., He MX; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard Biophysics Graduate Program, Harvard University, Boston, MA, USA., Braggio E; Department of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA., Fonseca R; Department of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA., Maruvka YE; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Guerriero JL; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Goldman M; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Van Allen EM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., McCarroll SA; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Azzi J; Harvard Medical School, Boston, MA, USA.; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Boston, MA, USA., Getz G; Harvard Medical School, Boston, MA, USA. gadgetz@broadinstitute.org.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. gadgetz@broadinstitute.org.; Massachusetts General Hospital, Boston, MA, USA. gadgetz@broadinstitute.org., Ghobrial IM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. irene_ghobrial@dfci.harvard.edu.
Publikováno v:
Nature cancer [Nat Cancer] 2020 May; Vol. 1 (5), pp. 493-506. Date of Electronic Publication: 2020 Apr 27.